Get started
Author

Sandeep Atla

Observed name: Atla, Sandeep
Observed institution: Texas A&M University
ORCID: 0000-0001-9960-5429
Observed ORCID: 0000-0001-9960-5429
OpenAlex ID: A5042724985
Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease
2024 · Yugendar R. Alugubelli, Jing Xiao, et al. · Journal of Medicinal Chemistry · 85
A Systematic Survey of Reversibly Covalent Dipeptidyl Inhibitors of the SARS-CoV-2 Main Protease
2023 · Zhi Zachary Geng, Sandeep Atla, et al. · Journal of Medicinal Chemistry · 29
PDF
Role of NLRP3 inflammasome in nanoparticle adjuvant-mediated immune response
2024 · Momitul Ahmed, Pavithra Kurungottu, et al. · Biomaterials Science · 23
PDF
Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors
2024 · Kaustav Khatua, Yugendar R. Alugubelli, et al. · Antiviral Research · 12
Ubiquitin Azapeptide Esters as Next-Generation Activity-Based Probes for Cysteine Enzymes in the Ubiquitin Signal Pathway
2025 · Saibal Chanda, Sandeep Atla, et al. · Journal of the American Chemical Society · 11
PDF
A Simple, Quick, and Scalable Route to Fluorogenic Ubiquitin and Ubiquitin-Like Protein Substrates for Assessing Activities of Deubiquitinases and Ubiquitin-Like Protein-Specific Proteases
2025 · Saibal Chanda, Alan Pham, et al. · ACS Chemical Biology · 4
PDF
Prioritization of Eleven-Nineteen-Leukemia Inhibitors as Orally Available Drug Candidates for Acute Myeloid Leukemia
2024 · Xuejiao Shirley Guo, Sandeep Atla, et al. · Journal of Medicinal Chemistry · 4
Nicotine-Inspired, De Novo-Designed SARS-CoV-2 Main Protease Inhibitors Reveal Unique Chemistry for Covalently Conjugating Both Cysteine and Histidine Residues in the Catalytic Dyad
2026 · Sandeep Atla, Veerabhadra Vulupala, et al. · Journal of the American Chemical Society · 3
PDF
An Azapeptide Platform in Conjunction with Covalent Warheads to Uncover High-Potency Inhibitors for SARS-CoV-2 Main Protease
2023 · Kaustav Khatua, Yugendar R. Alugubelli, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 3
PDF
From nicotine to SARS-CoV-2 antivirals with potent in vivo efficacy and a broad anti-coronavirus spectrum
2026 · Kaustav Khatua, Sandeep Atla, et al. · Nature Communications · 2
PDF
Targeted delivery platforms for in vivo immune cell engineering: emerging strategies for cancer immunotherapy
2026 · Hari Krishnareddy Rachamala, Sandeep Atla, et al. · Frontiers in Pharmacology
PDF
High-Throughput Screening Identifies Covalent Inhibitors with Unique Chemistry and Binding Modes for SARS-CoV-2 Main Protease
2026 · Sandeep Atla, Kai S. Yang, et al. · JACS Au
PDF
Works count: 14
Citation count: 175
H-index: 5
I10-index: 5
Year
Topic
Type